Enhancing the action of incretin hormones: A new whey forward?

Endocrinology

Volumn 147, Issue 7, 2006, Pages 3171-3172

  Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE; INCRETIN;

APPETITE; CELL FUNCTION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HORMONE ACTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GLUCAGON-LIKE PEPTIDE 1; HORMONES; HUMANS; INSULIN; MICE; MILK PROTEINS; PEPTIDES; RATS;

EID: 33745128793     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0494     Document Type: Short Survey

References (16)

1. Badman MK, Flier JS 2005 The gut and energy balance: visceral allies in the obesity wars. Science 307:1909-1914
2. Creutzfeldt W, Ebert R 1985 New developments in the incretin concept today. Diabetologia 28:565-573
3. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
4. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
5. Riddle MC, Drucker DJ 2006 Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29:435-449
6. Gunnarsson PT, Winzell MS, Deacon CF, Larsen MO, Jelic K, Carr RD, Ahrén B 2006 Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 147:3173-3180
7. Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R 2006 Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes 55:1484-1490
8. Mrestani-Klaus C, Fengler A, Faust J, Brandt W, Wrenger S, Reinhold D, Ansorge S, Neubert K 2000 N-terminal HIV-1 Tat nonapeptides as inhibitors of dipeptidyl peptidase IV. Conformational characterization. Adv Exp Med Biol 477:125-129
9. Gabrilovac J, Abramic M, Uzarevic B, Andreis A, Poljak L 2003 Dipeptidyl peptidase IV (DPPIV) enzyme activity on immature T-cell line R1.1 is down-regulated by dynorphin-A(1-17) as a non-substrate inhibitor. Life Sci 73:151-166
10. Hansen L, Deacon CF, Orskov C, Holst JJ 1999 Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356-5363
11. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
12. Belobrajdic DP, McIntosh GH, Owens JA 2004 A high-whey-protein diet reduces body weight gain and alters insulin sensitivity relative to red meat in Wistar rats. J Nutr 134:1454-1458
13. Frid AH, Nilsson M, Holst JJ, Bjorck IM 2005 Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr 82:69-75
14. Mortensen K, Christensen LL, Holst JJ, Orskov C 2003 GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 114:189-196
15. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM 2006 Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290:E550-E559
16. Brubaker PL, Anini Y 2003 Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 81:1005-1012